KR20140056297A - 신규한 결정 형태 - Google Patents

신규한 결정 형태 Download PDF

Info

Publication number
KR20140056297A
KR20140056297A KR1020147005011A KR20147005011A KR20140056297A KR 20140056297 A KR20140056297 A KR 20140056297A KR 1020147005011 A KR1020147005011 A KR 1020147005011A KR 20147005011 A KR20147005011 A KR 20147005011A KR 20140056297 A KR20140056297 A KR 20140056297A
Authority
KR
South Korea
Prior art keywords
crystalline
rti
disease
raman
relilla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147005011A
Other languages
English (en)
Korean (ko)
Inventor
메이-인 리
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20140056297A publication Critical patent/KR20140056297A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
KR1020147005011A 2011-09-01 2012-08-31 신규한 결정 형태 Ceased KR20140056297A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530104P 2011-09-01 2011-09-01
US61/530,104 2011-09-01
PCT/EP2012/067027 WO2013030374A1 (en) 2011-09-01 2012-08-31 Novel crystal form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197017797A Division KR20190075172A (ko) 2011-09-01 2012-08-31 신규한 결정 형태

Publications (1)

Publication Number Publication Date
KR20140056297A true KR20140056297A (ko) 2014-05-09

Family

ID=46829730

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147005011A Ceased KR20140056297A (ko) 2011-09-01 2012-08-31 신규한 결정 형태
KR1020197017797A Ceased KR20190075172A (ko) 2011-09-01 2012-08-31 신규한 결정 형태

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197017797A Ceased KR20190075172A (ko) 2011-09-01 2012-08-31 신규한 결정 형태

Country Status (34)

Country Link
US (3) US9227953B2 (https=)
EP (1) EP2751094B1 (https=)
JP (1) JP6199291B2 (https=)
KR (2) KR20140056297A (https=)
CN (1) CN103906744A (https=)
AU (2) AU2012300841C1 (https=)
BR (1) BR112014004251A2 (https=)
CA (1) CA2847066C (https=)
CL (1) CL2014000489A1 (https=)
CO (1) CO6890102A2 (https=)
CR (1) CR20140098A (https=)
CY (1) CY1120784T1 (https=)
DK (1) DK2751094T3 (https=)
DO (1) DOP2014000042A (https=)
EA (1) EA027972B1 (https=)
ES (1) ES2686563T3 (https=)
HR (1) HRP20181375T1 (https=)
HU (1) HUE041578T2 (https=)
IL (1) IL230977A (https=)
LT (1) LT2751094T (https=)
MA (1) MA35362B1 (https=)
MX (1) MX349243B (https=)
MY (1) MY172885A (https=)
PE (1) PE20141411A1 (https=)
PH (1) PH12014500382A1 (https=)
PL (1) PL2751094T3 (https=)
PT (1) PT2751094T (https=)
RS (1) RS57644B1 (https=)
SG (1) SG2014011886A (https=)
SI (1) SI2751094T1 (https=)
SM (1) SMT201800455T1 (https=)
UA (1) UA114607C2 (https=)
WO (1) WO2013030374A1 (https=)
ZA (1) ZA201401176B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2751094T1 (sl) * 2011-09-01 2018-10-30 Glaxo Group Limited Nova kristalinična oblika
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US12583835B2 (en) * 2020-03-30 2026-03-24 Jiangsu Yahong Meditech Co., Ltd. Crystal form of nitroxoline prodrug, pharmaceutical composition containing same, and preparation method therefor and application thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69309056T2 (de) 1992-06-10 1997-09-18 Nanosystems L.L.C., Collegeville, Pa. Oberflaechenmodifizierte nsaid nanopartikeln
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US20070166777A1 (en) 2004-04-16 2007-07-19 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
CN101687009A (zh) * 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2008140450A1 (en) * 2007-05-11 2008-11-20 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
EP2977452A3 (en) * 2007-05-11 2016-05-25 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2012037782A1 (en) 2010-09-20 2012-03-29 Glaxo Group Limited Tricyclic compounds, preparation methods, and their uses
KR101861883B1 (ko) 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
JP2013544854A (ja) 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
SI2751094T1 (sl) * 2011-09-01 2018-10-30 Glaxo Group Limited Nova kristalinična oblika
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme

Also Published As

Publication number Publication date
NZ621315A (en) 2016-06-24
HK1198534A1 (en) 2015-05-15
JP6199291B2 (ja) 2017-09-20
DK2751094T3 (en) 2018-08-20
HRP20181375T1 (hr) 2018-10-19
AU2012300841A1 (en) 2014-03-13
CN103906744A (zh) 2014-07-02
US20140213613A1 (en) 2014-07-31
CA2847066A1 (en) 2013-03-07
HUE041578T2 (hu) 2019-05-28
MY172885A (en) 2019-12-13
EP2751094A1 (en) 2014-07-09
AU2016200492B2 (en) 2017-04-20
ES2686563T3 (es) 2018-10-18
CL2014000489A1 (es) 2014-08-01
IL230977A (en) 2016-08-31
MX349243B (es) 2017-07-18
WO2013030374A1 (en) 2013-03-07
SMT201800455T1 (it) 2018-11-09
UA114607C2 (uk) 2017-07-10
CR20140098A (es) 2014-05-06
JP2014525428A (ja) 2014-09-29
PL2751094T3 (pl) 2018-11-30
IL230977A0 (en) 2014-03-31
EA027972B1 (ru) 2017-09-29
ZA201401176B (en) 2015-12-23
MA35362B1 (fr) 2014-08-01
SG2014011886A (en) 2014-05-29
AU2016200492A1 (en) 2016-02-18
EP2751094B1 (en) 2018-06-20
BR112014004251A2 (pt) 2017-03-21
DOP2014000042A (es) 2014-08-31
CA2847066C (en) 2019-04-30
PT2751094T (pt) 2018-10-19
EA201490536A1 (ru) 2014-08-29
US9694004B2 (en) 2017-07-04
US20160075685A1 (en) 2016-03-17
KR20190075172A (ko) 2019-06-28
CY1120784T1 (el) 2019-12-11
US9227953B2 (en) 2016-01-05
AU2012300841C1 (en) 2016-02-18
SI2751094T1 (sl) 2018-10-30
PE20141411A1 (es) 2014-10-29
MX2014002454A (es) 2014-04-10
CO6890102A2 (es) 2014-03-10
LT2751094T (lt) 2018-11-12
US20160367544A1 (en) 2016-12-22
PH12014500382A1 (en) 2021-07-12
US9682074B2 (en) 2017-06-20
RS57644B1 (sr) 2018-11-30
AU2012300841B2 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP6665169B2 (ja) 新規化合物αｖβ６インテグリンアンタゴニスト
CN107531678B (zh) Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
KR20210018557A (ko) 피롤 유도체의 결정 및 그 제조 방법
KR20140138941A (ko) 상피 성장 인자 수용체 키나제 억제제의 염
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
KR102576964B1 (ko) 헤테로시클리덴 아세트아미드 유도체의 결정
CN121889396A (zh) 用于治疗甲状腺眼病的林西替尼的结晶盐
US9694004B2 (en) Crystal form
TWI820182B (zh) 四氫哌喃基胺基－吡咯并嘧啶酮化合物的固體形式
WO2012090221A1 (en) Novel salts of imatinib
JP7736311B2 (ja) ピリミジノジアゼピン誘導体の結晶性形態
JPWO2014142056A1 (ja) ピロリジン−３−イル酢酸誘導体の塩およびその結晶
NZ621315B2 (en) Novel crystal form of rilapladib
HK1198534B (en) Novel crystal form
JP2022528025A (ja) ピリメタミンの酸付加塩

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170630

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181015

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181015

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190226

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190115

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170630

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190419

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190328

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190226

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190115

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20181015

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170630

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190620

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20190620

WITB Written withdrawal of application